Abu-Tair Lina, Axelrod Jonathan H, Doron Sarit, Ovadya Yossi, Krizhanovsky Valery, Galun Eithan, Amer Johnny, Safadi Rifaat
Liver & Gastroenterology Units; Division of Medicine, Hadassah Medical Center, Jerusalem, Israel.
PLoS One. 2013 Dec 10;8(12):e82571. doi: 10.1371/journal.pone.0082571. eCollection 2013.
The toll-like receptor-9 (TLR9) agonist cytosine phosphate guanine (CpG), activates hepatic stellate cells (HSCs) and mediates fibrosis. We investigated the TLR9 effects on lymphocyte/HSCs interactions. Liver fibrosis was induced in wild-type (WT) mice by intra-peritoneal carbon-tetrachloride (CCl4) induction for 6 weeks. Fibrotic groups were intravenously treated by a vehicle versus CpG along last 2 weeks. Compared to vehicle-treated fibrotic WT, the in-vivo CpG-treatment significantly attenuated hepatic fibrosis and inflammation, associated with decreased CD8 and increased NK liver cells. In-vitro, co-cultures with vehicle-treated fibrotic NK cells increased HSCs proliferation (P<0.001) while their CpG-treated counterparts achieved a significant decrease. To investigate the role of lymphocytes, TLR9(-/-) mice induced-hepatic fibrosis were used. Although TLR9(-/-) mice manifested lower fibrotic profile as compared to their wild-type (WT) counterparts, senescence (SA-β-Gal activity) in the liver and ALT serum levels were significantly greater. In an adoptive transfer model; irradiated WT and TLR9(-/-) recipients were reconstituted with naïve WT or TLR9(-/-) lymphocytes. The adoptive transfer of TLR9(-/-) versus WT lymphocytes led to increased fibrosis of WT recipients. TLR9(-/-) fibrotic recipients reconstituted with TLR9(-/-) or WT lymphocytes showed no changes in hepatic fibrosis severity or ALT serum levels. TLR9 activation had inconsistent effects on lymphocytes and HSCs. The net balance of TLR9 activation in WT, displayed significant anti-fibrotic activity, accompanied by CD8 suppression and increased NK-cells, activity and adherence to HSCs. The pro-fibrotic and pro-inflammatory properties of TLR9(-/-) lymphocytes fail to activate HSCs with an early senescence in TLR9(-/-) mice.
Toll样受体9(TLR9)激动剂胞嘧啶磷酸鸟嘌呤(CpG)可激活肝星状细胞(HSC)并介导纤维化。我们研究了TLR9对淋巴细胞/HSC相互作用的影响。通过腹腔注射四氯化碳(CCl4)诱导野生型(WT)小鼠肝纤维化6周。在最后2周,纤维化组分别静脉注射溶剂对照或CpG。与溶剂对照处理的纤维化WT小鼠相比,体内CpG处理显著减轻了肝纤维化和炎症,同时CD8细胞减少,肝内NK细胞增加。在体外,与溶剂对照处理的纤维化NK细胞共培养可增加HSC增殖(P<0.001),而与CpG处理的NK细胞共培养则显著降低HSC增殖。为了研究淋巴细胞的作用,我们使用了诱导肝纤维化的TLR9基因敲除(-/-)小鼠。尽管与野生型(WT)小鼠相比,TLR9基因敲除(-/-)小鼠的纤维化程度较低,但其肝脏衰老(SA-β-Gal活性)和血清ALT水平显著更高。在过继转移模型中,对受照射的WT和TLR9基因敲除(-/-)受体小鼠输入未经刺激的WT或TLR9基因敲除(-/-)淋巴细胞进行重建。输入TLR9基因敲除(-/-)淋巴细胞与输入WT淋巴细胞相比,导致WT受体小鼠的纤维化增加。用TLR9基因敲除(-/-)或WT淋巴细胞重建的TLR9基因敲除(-/-)纤维化受体小鼠,其肝纤维化严重程度或血清ALT水平均无变化。TLR9激活对淋巴细胞和HSC的影响不一致。WT小鼠中TLR9激活的净平衡显示出显著的抗纤维化活性,同时伴有CD8细胞受抑制以及NK细胞活性增加和对HSC的黏附增强。TLR9基因敲除(-/-)淋巴细胞的促纤维化和促炎特性无法激活TLR9基因敲除(-/-)小鼠中出现早期衰老的HSC。